S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:GLUE

Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

$7.04
+0.45 (+6.83%)
(As of 03/27/2024 ET)
Today's Range
$6.67
$7.22
50-Day Range
$4.26
$8.46
52-Week Range
$2.44
$8.84
Volume
146,655 shs
Average Volume
154,119 shs
Market Capitalization
$353.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Monte Rosa Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
56.3% Upside
$11.00 Price Target
Short Interest
Bearish
5.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.25) to ($2.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.64 out of 5 stars

Medical Sector

713th out of 939 stocks

Biological Products, Except Diagnostic Industry

119th out of 154 stocks

GLUE stock logo

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

GLUE Stock Price History

GLUE Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Monte Rosa Therapeutics: Q4 Earnings Insights
Monte Rosa Therapeutics Inc GLUE
Monte Rosa Therapeutics: Q3 Earnings Insights
See More Headlines
Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GLUE
Fax
N/A
Employees
133
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+56.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-135,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.58 per share

Miscellaneous

Free Float
47,496,000
Market Cap
$353.06 million
Optionable
Optionable
Beta
1.43
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Markus Warmuth M.D. (Age 52)
    President, CEO & Director
    Comp: $901.35k
  • Dr. Owen B. Wallace Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $630.68k
  • Dr. Filip Janku M.D. (Age 49)
    Ph.D., Chief Medical Officer
    Comp: $658.66k
  • Ms. Jennifer Champoux
    Chief People & Operations Officer
  • Dr. Sharon Townson Ph.D. (Age 49)
    Chief Technology Officer
  • Dr. John C. Castle Ph.D. (Age 52)
    Chief Data & Information Officer
  • Mr. Andrew Funderburk
    Senior VP and Head of IR & Strategic Finance
  • Mr. Philip Nickson J.D. (Age 45)
    Ph.D., General Counsel
  • Mr. Magnus Walter DPHIL
    Senior Vice President of Drug Discovery
  • Mr. Edmund Dunn (Age 58)
    Vice President & Corporate Controller

GLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Monte Rosa Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GLUE shares.
View GLUE analyst ratings
or view top-rated stocks.

What is Monte Rosa Therapeutics' stock price target for 2024?

3 brokers have issued twelve-month target prices for Monte Rosa Therapeutics' stock. Their GLUE share price targets range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 56.3% from the stock's current price.
View analysts price targets for GLUE
or view top-rated stocks among Wall Street analysts.

How have GLUE shares performed in 2024?

Monte Rosa Therapeutics' stock was trading at $5.65 at the beginning of the year. Since then, GLUE stock has increased by 24.6% and is now trading at $7.04.
View the best growth stocks for 2024 here
.

When is Monte Rosa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GLUE earnings forecast
.

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.01.

What ETF holds Monte Rosa Therapeutics' stock?

Range Cancer Therapeutics ETF holds 18,664 shares of GLUE stock, representing 1.26% of its portfolio.

When did Monte Rosa Therapeutics IPO?

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share.

Who are Monte Rosa Therapeutics' major shareholders?

Monte Rosa Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.87%), Price T Rowe Associates Inc. MD (9.87%), Vanguard Group Inc. (3.17%), Vanguard Group Inc. (3.17%), Northern Trust Corp (0.57%) and Charles Schwab Investment Management Inc. (0.49%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLUE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners